Literature DB >> 9815588

Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.

S M Yule1, L Price, A D Pearson, A V Boddy.   

Abstract

Although both cyclophosphamide (CP) and ifosfamide (IF) are used in the treatment of central nervous system tumors, little is known about the concentration of either drug or their metabolites in the cerebrospinal fluid (CSF) of children. The concentrations of the parent oxazaphosphorine and its principal metabolites were measured simultaneously in the plasma and CSF of 25 children. Twenty-one patients received CP for the treatment of either acute lymphoblastic leukemia, non-Hodgkin's lymphoma, or medulloblastoma, and 4 children received IF for the treatment of rhabdomyosarcoma. A high degree of interpatient variation was seen in terms of the CSF concentration of CP and the CSF:plasma ratio. The CSF:plasma ratio was greater for IF than for CP (P < 0.001). In contrast to IF, where the majority of metabolites was measured in the CSF, no child receiving CP had detectable metabolites. Children receiving dexamethasone had lower concentrations of CP in the CSF (P = 0.04). The CSF:plasma ratio for isophosphoramide mustard was greater than that for either parent drug or any other metabolite. These results demonstrate that IF enters the CSF to a greater extent than CP in children. The ability of both IF and CP and their metabolites to cross the blood-brain barrier may be reduced by dexamethasone.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815588

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

Review 1.  Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.

Authors:  Megan O Jacus; Vinay M Daryani; K Elaine Harstead; Yogesh T Patel; Stacy L Throm; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 3.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

Review 4.  Pharmacokinetic considerations in the treatment of CNS tumours.

Authors:  Susannah Motl; Yanli Zhuang; Christopher M Waters; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial.

Authors:  Kristoph Jahnke; Agnieszka Korfel; Julia Komm; Nikolaos E Bechrakis; Harald Stein; Eckhard Thiel; Sarah E Coupland
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-16       Impact factor: 3.117

6.  Ifosfamide or trofosfamide in patients with intraocular lymphoma.

Authors:  Kristoph Jahnke; Eckhard Thiel; Nikolaos E Bechrakis; Gregor Willerding; Dale F Kraemer; Lars Fischer; Agnieszka Korfel
Journal:  J Neurooncol       Date:  2008-12-20       Impact factor: 4.130

Review 7.  Treatment of primary intraocular lymphoma with oral trofosfamide: report of two cases and review of the literature.

Authors:  Kristoph Jahnke; Nikolaos E Bechrakis; Sarah E Coupland; Alexander Schmittel; Michael H Foerster; Lars Fischer; Eckhard Thiel; Agnieszka Korfel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09       Impact factor: 3.117

Review 8.  Position paper: Rationale for the treatment of children with CCSK in the UMBRELLA SIOP-RTSG 2016 protocol.

Authors:  Saskia L Gooskens; Norbert Graf; Rhoikos Furtwängler; Filippo Spreafico; Christophe Bergeron; Gema L Ramírez-Villar; Jan Godzinski; Christian Rübe; Geert O Janssens; Gordan M Vujanic; Ivo Leuschner; Aurore Coulomb-L'Hermine; Anne M Smets; Beatriz de Camargo; Sara Stoneham; Harm van Tinteren; Kathy Pritchard-Jones; Marry M van den Heuvel-Eibrink
Journal:  Nat Rev Urol       Date:  2018-02-27       Impact factor: 14.432

9.  Early Effects of Cyclophosphamide, Methotrexate, and 5-Fluorouracil on Neuronal Morphology and Hippocampal-Dependent Behavior in a Murine Model.

Authors:  Julie E Anderson; Madison Trujillo; Taylor McElroy; Thomas Groves; Tyler Alexander; Frederico Kiffer; Antiño R Allen
Journal:  Toxicol Sci       Date:  2020-01-01       Impact factor: 4.849

Review 10.  Drug interactions at the blood-brain barrier: fact or fantasy?

Authors:  Sara Eyal; Peng Hsiao; Jashvant D Unadkat
Journal:  Pharmacol Ther       Date:  2009-04-22       Impact factor: 13.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.